[Multiple sclerosis, the therapeutic arsenal of today and tomorrow].
Zéphir
Hélène
H
Service de Neurologie, Pôle de Neurologie, Hôpital Roger-Salengro, Centre Hospitalier Régional Universitarie, Lille. h-zephir@chru-lille.fr
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D015984:Causality; D017338:Cladribine / Q000627:therapeutic use; D006233:Persons with Disabilities / Q000706:statistics & numerical data; D000068876:Fingolimod Hydrochloride; D005544:Forecasting; D005602:France / Q000453:epidemiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D011409:Propylene Glycols / Q000627:therapeutic use; D012106:Research / Q000639:trends; D013110:Sphingosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014611:Vaccination / Q000639:trends; D019444:Vaccines, DNA / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; C544595:BHT 3009; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D019444:Vaccines, DNA; D000074323:Alemtuzumab; D017338:Cladribine; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine